OM
VYGR icon

Opaleye Management’s Voyager Therapeutics VYGR Stock Holding History

Opaleye Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.44M Sell
1,150,000
-46,904
-4% -$185K 0.58% 34
2025
Q4 		$4.7M Buy
+1,196,904
New +$5.29M 0.62% 31

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Opaleye Management's VYGR Position: Q1 2026 in Review

Opaleye Management reduced its Voyager Therapeutics (VYGR) stake by 3.9% in Q1 2026, selling an estimated $185K and leaving 1,150,000 shares worth $4.44M. The position accounts for 0.58% of the portfolio, ranked #34.

Opaleye Management first reported a position in VYGR in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.7M in Q4 2025. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.

  • Opaleye Management held 1,150,000 shares of Voyager Therapeutics worth $4.44M as of Q1 2026.
  • Opaleye Management sold 46,904 Voyager Therapeutics shares in Q1 2026, an estimated $185K.
  • Voyager Therapeutics made up 0.58% of Opaleye Management's portfolio in Q1 2026, its #34 holding.
  • Opaleye Management first reported a position in Voyager Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Opaleye Management's Voyager Therapeutics position peaked at $4.7M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.